Research programme: PCSK 9 inhibitors - Pfizer/ University of Queensland Institute for Molecular Bioscience

Drug Profile

Research programme: PCSK 9 inhibitors - Pfizer/ University of Queensland Institute for Molecular Bioscience

Alternative Names: PCSK 9 vaccine - Pfizer

Latest Information Update: 02 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer; University of Queenslands Institute for Molecular Bioscience
  • Class Peptides; Small molecules; Vaccines
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Lipid metabolism disorders

Most Recent Events

  • 13 Jan 2015 Preclinical trials in Cardiovascular disorders in USA (PO)
  • 13 Jan 2015 Preclinical trials in Cardiovascular disorders in USA (Parenteral)
  • 13 Jan 2015 Preclinical trials in Lipid metabolism disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top